Methods and Compositions for Generating Pancreatic Progenitors and Functional Beta Cells from hPSCs

• US 20150104430A1
• Filed: 04/30/2013
• Published: 04/16/2015
• Est. Priority Date: 04/30/2012
• Status: Active Application

• Current Assignee: University Health Network
• Original Assignee: University Health Network
• Inventors: Keller, Gordon, Nostro, Maria Cristina, Holtzinger, Audrey, Sarangi, Farida
• Application Number:
  US14/397,657
• Publication Number:
  US 20150104430A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/119 Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/385 of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
• CPC Class Codes: C12N 2501/40 Regulators of development
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2502/28 Vascular endothelial cells
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/45 from artificially induced pluripotent stem cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells
• CPC Class Codes: C12N 5/0678 Stem cells; Progenitor cells; Precursor cells

Abstract

Methods and compositions for producing NKX6-1+ pancreatic progenitor cells and/or insulin producing cells from an endodermal cell population, the method comprising contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination of at least one EGF component and at least one nicotinamide component to induce the differentiation of at least one endodermal cell into a NKX6-1+ pancreatic progenitor cell, the combination optionally further comprising at least one Noggin component.

Claims

1. A method of producing NKX6-1+ pancreatic progenitor cells from an endodermal cell population, the method comprising contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination of at least one EGF component and at least one nicotinamide component to induce the differentiation of at least a portion of the endodermal cell population into NKX6-1+ pancreatic progenitor cells, the combination optionally further comprising at least one Noggin component.

2. The method of claim 1 wherein the Noggin component comprises one or more of Noggin and/or active conjugates and/or fragments thereof;

BMPR1A and/or active conjugates and/or fragments thereof;

BMPR1B and/or active conjugates and/or fragments thereof;

Dorsomorphin and/or salts or solvates thereof;

LDN 193189, also known as “

DM-3189”

, and/or salts and/or solvates thereof;

CHORDIN and/or active conjugates and/or fragments thereof; and

/or any combination of two or more thereof, optionally wherein the Noggin component is Noggin.

4. The method of claim 1 wherein the EGF component comprises EGF and/or active conjugates and/or fragments thereof;

Amphiregulin (AR) and/or active conjugates and/or fragments thereof;

Transforming Growth Factor α

(TGFα

) and/or active conjugate and/or fragments thereof;

Betacellulin (BTC) and/or active variants and/or fragments thereof;

Epiregulin (EPR) and/or active variants and/or fragments thereof;

Neuregulins (including for example NRG1, NRG2, 3 NRG4) and/or active variants and/or fragments thereof; and

/or combinations of two or more thereof.

5. The method of claim 4, wherein the EGF component is EGF and/or an active conjugate and/or fragment thereof, optionally wherein the EGF conjugate is Heparin-binding EGF (HB-EGF).

7. The method of claim 1, wherein the Nicotinamide component comprises nicotinamide (also known as niacinamide and nicotinic acid amide), salts, solvates and conjugates thereof;

Poly(ADP-ribose) synthetase inhibitors such as benzamide and/or 3-aminobenzamide;

Sir-2 inhibitors such as sirtinol, M15, splitomicin;

HDAC inhibitors such as AN-9, CI-994, FK228, LAQ-824, MS275, SAHA, Valproic Acid, TSA, Sodium Butyrate, and/or combinations of two or more thereof, optionally wherein the Nicotinamide component is Nicotinamide and/or a salt, solvate and/or conjugate thereof.

9. The method of claim 1, wherein the combination of at least one Noggin component, at least one EGF component, and at least one nicotinamide component comprises Noggin, EGF and nicotinamide (e.g. NENA).

10. The method of claim 1, further comprising an Exendin-4 component, optionally wherein the Exendin-4 component is Exendin-4.

12. The method of claim 1, wherein the endodermal cell population is differentiated from pluripotent stem cells (PSCs) such as an embryonic stem cell (ESC) or an induced pluripotent stem cells (iPSCs), optionally wherein the pluripotent stem cell is a human ESC (hESC) or a human iPSC (hiPSC).

14. The method of claim 1, first comprising producing an endodermal cell population.

15. The method of claim 14, wherein the method of producing the endodermal cell population comprises one or more of steps (or substeps) a, b and c;

and step d, the steps comprising;

a) contacting a pluripotent stem cell population with a combination of;

I) a nodal agonist, optionally ActA and a wnt signaling agonist, optionally Wnt3a or CIHR 99021,

II) a nodal agonist, optionally Act A, a FGF agonist, optionally bFGF and optionally a wnt signaling agonist, optionally Wnt3a CIHR 99021; and

III) a nodal agonist, optionally ActA and a FGF agonist, optionally bFGF;

to produce Stage 1 differentiated cells;

b) contacting the Stage I differentiated cells with a FGF agonist, optionally FGF10, and optionally wnt signaling agonist, optionally Wnt3a and/or a noggin component, optionally Dorsomorphin, to produce Stage 2 differentiated cells;

c) contacting the Stage 2 differentiated cells with a Noggin component, optionally Noggin, Retinoic acid (RA) or RA analog, and optionally cyclopamine-KAAD (Cyc), a FGF agonist, optionally FGF10 and/or an Exendin-4 component, optionally Exendin-4 to provide a endodermal cell population; and

d) contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination comprising at least one EGF component and at least one nicotinamide component in an amount sufficient to induce the differentiation of at least a portion of the endodermal cell population into NKX6-1+ pancreatic progenitor cells.

16. A method for generating a NKX6-1+ insulin producing cell population comprising:

a. producing a population of cells comprising NKX6-1 positive pancreatic progenitor cells according to the method of claim 1; and

b. introducing the population of cells, or an NKX6-1 enriched or isolated population, into a subject.

17. A method for generating an insulin producing cell comprising:

a. generating a population of cells comprising NKX6-1 positive pancreatic progenitor cells, optionally produced according to the method of claim 1;

b. co-culturing the NKX6-1 positive pancreatic progenitor cells with CD34+ endothelial cells.

19. The method of claim 1 comprising enriching or isolating a NKX6-1 positive population of cells.

20. The method of claim 19, wherein the enriching or isolating step comprises contacting the population of cells with an HPx epitope detecting antibody and isolating or partially purifying the HPx1 and/or HPx2 bound subpopulation of cells, optionally wherein the HPx epitope detecting antibody is HPx1 and/or HPx2.

22. An enriched and/or isolated NKX6-1 positive cell population produced according to the method of claim 19 and/or a composition comprising said cell population and a suitable diluent.

23. The enriched NKX6-1 positive cell population of claim 22 comprising at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or up to about 95% NKX6-1 positive cells.

24. The isolated NKX6-1 positive cell population of claim 23, comprising at least 30%, 35%, 40% or at least 50% NKX6-1 positive pancreatic progenitor cells and/or comprising at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or up to about up to 95% NKX6-1 positive insulin producing cells.

3. (canceled)

6. (canceled)

8. (canceled)

11. (canceled)

13. (canceled)

18. (canceled)

21. (canceled)

25. (canceled)

26. A culture medium supplement composition comprising an EGF component, a Nicotinamide component and optionally a Noggin component and/or an Exendin-4 component.

27. A culture medium culture composition comprising a suitable base culture medium and the culture medium supplement composition of claim 26.

28. A kit comprising:

an EGF component,

a Nicotinamide component; and

/or

a Noggin component and/or

optionally an Exendin-4 component.

29. (canceled)